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Inhaled irritants and allergens initiate a
pulmonary chemoreflex that can result in
responses both in the lung and heart as well as
in the systemic and the peripheral vascula-
tures. These responses are due to both neural
reﬂexes and the activation of humoral recep-
tors by circulating mediators (1). Histamine, a
major mediator released by IgE activation,
participates in many of the immediate car-
diopulmonary physiologic consequences of
inhaled antigen in both humans (2) and dogs
(3). Histamine is released from mast cells and
basophils in the alveolar interstitium and in
bronchial mucosa. The number of mast cells
in the alveoli (350/mm2) (4) markedly exceeds
that in the bronchial mucosa, 226/mm2 (5)
when the relative surface areas of each are con-
sidered. Histamine can activate pulmonary C
fibers (6), bronchial C fibers (7), and
bronchial irritant fibers (6,8). The stimula-
tion of select subsets of each of these fibers
has been shown to increase broncho-
pulmonary smooth muscle tone (9) and elicit
the pulmonary chemoreﬂex typiﬁed by rapid
shallow breathing, bradycardia, and hypoten-
sion. Histamine (10) and inhaled allergens
(11) stimulate mucociliary transport. As the
functions of the respiratory central pattern
generator, bronchial and vascular smooth
muscle, and the mucosa are quite distinct, the
relative responses of and pathways through
which each of these responds to histamine
and allergens must each be evaluated.
To determine the relative cardiovascular,
respiratory, and epithelial responses elicited by
histamine administered to the alveolar,
bronchial, and vascular compartments and the
role of neural pathways in mediating these
events, we conducted a series of experiments
in beagle dogs. In addition we evaluated car-
diovascular, respiratory, and epithelial
responses elicited by ragweed allergen admin-
istered to the alveolar and bronchial compart-
ments in a cohort of ragweed-sensitized dogs
and nonsensitized siblings. Activation of the
pulmonary chemoreﬂex was demonstrated by
the measurements of respiratory rate, heart
rate, and arterial blood pressure. Efferent
responses of the mucosa were assayed in terms
of mucociliary clearance, whereas responses of
smooth muscles were indicated by either pul-
monary resistance or transpulmonary pressure
and compliance. Indication of histamine or
allergen-induced impairment of gas exchange
was determined from the measurement of
minute ventilation and arterial blood gases. In
these experiments, equivalent total masses of
histamine (approximately 185 µg) deposited
in the lungs were partitioned such that in one
set of experiments 71% was deposited in the
bronchi; in the other set 91% was deposited
in the alveoli. Responses from the predomi-
nantly alveolar deposition due to the 9%
deposited in the bronchi were assessed sepa-
rately by depositing 16 µg in the bronchi. The
contribution of vagal transmission was
ascertained following bilateral sectioning of
the vagosympathetic trunks. To evaluate the
extent to which histamine-induced responses
due to its translocation from the airways to
the blood were transmitted via the central ner-
vous system (12) or from direct cardiovascular
regulation, we administered 200 µg of hista-
mine intravenously (iv) to dogs with and
without bilateral vagotomy. To evaluate the
extent to which the histamine-induced
responses could be attenuated by an anti-
asthma agent that stabilizes cell membranes
and, similar to cromolyn sodium (13) likely
desensitizes sensory nerves, we administered
nedocromil before administering histamine.
In the experiments in which ragweed was
administered, 0.4–1.8 µg ragweed were
deposited in the lungs. During bronchial
deposition 37% was deposited in the bronchi
and during alveolar deposition 90% was
deposited in the alveoli (11).
Methods
Experimental procedures were approved by the
Animal Care Committee at the University of
Illinois at Chicago. The beagle dogs were either
obtained from the Chicago School of Medicine
(North Chicago, IL, USA) or Veterans Affairs
(Westside Division, Chicago, IL, USA) or bred
at the University of Chicago (Chicago, IL,
USA). They were conditioned and housed in a
controlled environment at the University of
Illinois at Chicago, which is approved by the
American Association for Accreditation of
Laboratory Animal Care. Studies were sepa-
rated by intervals of at least 1 week.
Experiments on histamine were conducted on
10 adult beagle dogs (3 females, 7 males)
weighing 11.0 ± 0.4 kg. Cardiac responses are
reported for 5 of 7 dogs sensitized to ragweed
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allergen. These data are derived from the raw
data of a study previously published (11). 
Delivery of Aerosols to the Bronchi 
and Alveoli
Two aerosol delivery systems were developed
to deposit aerosols selectively in the lower res-
piratory tract of anesthetized beagles. One sys-
tem delivered aerosols predominantly in the
bronchial airways; the other delivered aerosols
predominantly in the alveolar lung regions. At
the time of an aerosol challenge, the dog’s
endotracheal tube was connected to either sys-
tem. In the histamine study, both systems
delivered aerosols created by an ultrasonic
nebulizer (Microstat, Mountain Medical
Equipment, Inc., Littleton, CO, USA),
whereas in the allergen study, predominant
bronchial deposition was obtained using a
Fisoneb (Fisons Corp., Rochester, NY, USA)
(mass median diameter of 5.5 µm). The sys-
tems were grounded to minimize aerosol loss
due to electrostatic charge. Volume-controlled
logic and timing circuitry was used to activate
a sequence of solenoid valves (Automatic
Switch Co., Florham Park, NJ, USA) to effect
the desired aerosol delivery while maintaining
adequate ventilation. In the histamine
bronchial delivery system, the nebulizer was
modiﬁed by removing the “ﬁns,” deﬂector baf-
fle, and the valve; an additional tube was
inserted between the nebulizer and the mouth-
piece tube. A warmed humidiﬁer placed at the
input provided a source of moisture for parti-
cle growth. The tubing enroute to the nebu-
lizer was warmed to prevent condensation. For
deposition of aerosols predominantly into the
bronchial lung region, the bronchial deposi-
tion system was set to deliver a 200- to 210-
mL aerosol bolus 20 times per min at 60
L/min. Inhalation time was 0.2 sec and exhala-
tion time was 2 sec followed by a 0.8-sec delay.
In the alveolar aerosol delivery system, the only
modiﬁcation to the nebulizer was the removal
of the one-way valve. Dry air from the com-
pressed air source was not humidified. The
aerosol delivery tubing was warmed to prevent
aerosol growth by condensation. For deposi-
tion of aerosols predominantly into the alveo-
lar regions, the system was set to deliver a
160-mL aerosol bolus followed by a 160- to
165-mL air bolus at 13–20 L/min at a rate of
about 7 times per minute. Inhalation time was
1 sec, followed by a 5-sec breath hold; exhala-
tion time was 2 sec followed by a 1-sec delay.
Volume outputs were calibrated with a Collins
respirometer (Collins, Braintree, MA, USA). 
Dosimetry of Histamine and
Nedocromil Aerosols Deposited 
in the Bronchi and Alveoli
Before conducting the physiologic protocols,
the radioaerosol particulate tracer distribution
within the aerosol according to particle size
and attenuation of activity in the dog’s lungs
was determined. The particle size generated
by the nebulizer as provided by the manufac-
turer (without the valve) was measured at a
flow rate of 28 L/min. The nebulizer was
loaded with 2.5 mL of a 2-mg/mL ﬂuorescein
solution and 2.5 mL of a Tc99m sulfur colloid
solution; particle size was determined using a
cascade impactor (Andersen 1ACFM Mark
II; Andersen Samplers, Inc., Atlanta, GA,
USA). The mass median diameter ± the geo-
metric standard deviation was 1.7 µm ± 1.6
based on the absorbance of fluorescein and
1.6 µm ± 1.4 based on the counting of Tc99m
activity. Nebulizer output consistency was
checked periodically by collecting a fluores-
cein sodium (Sigma, St. Louis, MO, USA)
aerosol on a filter, redissolving the particles
into saline, and running a spectrophotometric
assay for ﬂuorescein. The counting efﬁciency
of the gamma camera (Siemens, Chicago, IL,
USA) to radioactivity deposited in the dog’s
lungs was determined by iv injection of a
known amount of Tc99m-labeled albumin
aggregate (Medi-Physics, Richmond, CA,
USA) in an anesthetized dog. With this tech-
nique (13) the macroagregates were assumed
to lodge within the capillaries of the lung.
Radioisotope calibration was performed with
a radioisotope calibrator (model CRC-7;
Capintec Inc., Ramsey, NJ, USA). 
The mass of aerosol deposited per breath
in the bronchi and alveoli was measured for
both the bronchial and alveolar aerosol deliv-
ery systems for each of the 10 dogs in the hist-
amine study and 7 dogs in the ragweed study.
The fasted dog was anesthetized, restrained in
the supine position on the gamma camera,
and intubated. A radioaerosol consisting of
Tc99m-labeled sulfur colloid (Medi-Physics,
Inc.) was delivered to the lung using the
bronchial or alveolar delivery systems. The
animal was extubated prior to counting the
radioactivity in the lung. Scintigrams (Figure
1) revealed the separation of radioactivity in
the bronchial and alveolar regions of the
lungs. The radioactivity measured in the lungs
was corrected for background activity and
radioactive decay. This retention of activity
represented total deposition in the lung. The
retention of radioactivity measured in the
lungs 24 hr after radioaerosol inhalation (fol-
lowing subtraction of background and correc-
tion for radioactive decay) was taken to
represent the mass of aerosol deposited in the
alveoli (14). This is based on the assumption
that particles deposited in the bronchi are
removed by mucociliary activity within 24 hr.
The activity remaining after subtraction of the
alveolar deposition from the total deposition
represents bronchial deposition (1). The fol-
lowing volumes were calculated from the spe-
ciﬁc activity in the nebulizer. In the histamine
study, the bronchial system delivered per
breath to the lungs volumes of 0.7 µL, of
which 0.5 µL was deposited in the bronchi
and 0.2 µL in the alveoli; the alveolar system
delivered a total lung volume of 2.3 µL, of
which 0.2 µL was deposited in the bronchi
and 2.1 µL in the alveoli. The masses of hista-
mine and nedocromil deposited in each of the
protocols (Table 1) were calculated from these
volumes for both the bronchial and alveolar
delivery systems. In the allergen study, in the
bronchial mode, 34 µ (SE: n = 7) was
deposited in 20 breaths, 37% of which was
deposited in the bronchi; in the alveolar
mode, 40 µ per 10 breaths was deposited,
90% of which was deposited in the alveoli. 
Assays
Pulmonary Mechanics
In the histamine study, transpulmonary pres-
sure (Ptp) and air flow (F) signals from the
differential pressure transducers (model
Figure 1. Scintigrams taken after predominantly bronchial (A) and alveolar (B) radioaerosol depositions.Allergen/mediator-induced cardiopulmonary responses
MP45-28-871, 50 cmH2O; model MP45-1-
871 2 cmH2O, respectively; Validyne
Engineering Corp., Northridge, CA, USA)
were ampliﬁed by a Buxco Preampliﬁer Bank
and analyzed by an analog Buxco pulmonary
mechanics analyzer (model 6; Buxco
Electronics, Inc., Sharon, CT, USA). The iso-
volumetric reference algorithm (Program 1)
of the Buxco pulmonary mechanics analyzer
was used to derive tidal volume (VT), respira-
tory rate (RR), minute volume (MV), lung
resistance (RL), and dynamic compliance
(Cdyn). The derived Ptp, F, VT, RR, MV, RL,
and Cdyn signals from the Buxco pulmonary
mechanics analyzer were simultaneously sam-
pled at a rate of 10 Hz/channel using an A/D
converter board (model 2905; Data
Translations, Marlboro, MA, USA) installed
in a 386-16 computer, IBM-80 (IBM,
Armonk, NY, USA) and stored permanently
on diskettes for later off-line, breath-by-
breath analysis on an IBM 4340 mainframe.
This system was calibrated using a volumetric
syringe for volume, a water manometer for
pressure, and with an internal calibration pro-
cedure provided within the Buxco. In the rag-
weed study a similar but updated system was
used (11).
Tracheal Ciliary Beat Frequency
In the histamine study, tracheal ciliary beat
frequency (CBFt) was measured using a non-
stationary heterodyne laser light-scattering
system (15). Briefly, an He-Ne laser beam
was transmitted down the axis of a hollow
stainless steel probe (30 cm long, 4.5 mm ID
and 8 mm OD). The beam exited perpendic-
ularly from the probe and was focused on a
7-µm focal spot coincident with the surface of
the ciliated epithelium 5 mm from the probe
surface. The predominant frequency of the
signals resulting from the scattered photons
derived from a time-frequency bilinear distri-
bution was deﬁned as CBFt. CBFt was calcu-
lated approximately every 3.5–5 sec. The
system was calibrated using a stroboscope.
Protocols
Animal Preparation for Challenges
Histamine study. Before each experiment, dogs
were fasted for 12 hr but allowed access to
water. Each dog was anesthetized with 2.5%
thiamylal sodium iv to effect (loss of palpebral
and toe-pinch reﬂexes), restrained in a supine
position, and intubated with a size 7 Hi-Lo Jet
(Mallinckrodt, Inc., St. Louis, MO, USA)
endotracheal tube (in one dog, a size 6 endo-
tracheal tube was used). The cuff of the endo-
tracheal tube was inﬂated in the distal trachea.
Supplemental doses of thiamylal sodium were
given throughout the study as needed to mini-
mize palpebral and toe-pinch reflexes. A
catheterized esophageal balloon (1.5 × 10 cm)
was fed through the esophagus and connected
to a 50 cmH2O differential pressure transducer
(model MP45-28-871; Validyne Engineering
Corp.). The other port of the pressure trans-
ducer was connected to the largest side port of
the endotracheal tube. This differential pres-
sure represented Ptp. The probe for measuring
ciliary beat frequency was carefully inserted on
the ventral side of the tracheal lumen such that
the laser beam focal spot coincided with the
lateral wall of the mid-trachea. The proximal
end of the endotracheal tube was connected to
a heated (37°C) pneumotach (model 3700,
0–160 L/min, Hans Rudolph, Inc., Kansas
City, MO, USA) coupled to a 2 cmH2O dif-
ferential pressure transducer (model MP45-1-
871, Validyne Engineering Corp.) to measure
ﬂow rate. The femoral artery was cannulated
to both monitor arterial blood pressure (BP)
(model P23ID; Gould Statham Instruments
Inc., Cleveland, OH, USA) and to sample
blood for blood chemistry measurements
(model 1312 BGM; Instrumentation
Laboratory, Inc., Lexington, MA, USA). Heart
rate, partial pressure of oxygen in blood
(SpO2) (pulse oximetry ﬁnger probe clamped
to tongue), end-tidal CO2 (carbon dioxide),
respiratory rate (model ULT-S-27-00; Datex,
Tewksbury, MA, USA), electrocardiogram
(model EK/5A; Burdick Corp.; model
78312A; Hewlett Packard, Waltham, MA,
USA), and rectal temperature (model 5800;
Omega Engineering, Inc., Stanford, CT, USA)
were monitored continuously. Arterial BP and
the pulmonary mechanics parameters previ-
ously described were recorded on the 6-chan-
nel chart recorder (model 2600; Gould, Inc.,
Cleveland, OH, USA). 
Bronchial and Alveolar Histamine
Inhalation Challenges
The experimental design is described in detail
in Table 1. Studies a–i were performed in sep-
arate experiments for each dog. Each dog was
allowed at least 1 week recuperation between
experiments. Eight experiments (studies a and
c–i) were performed in each of 10 anes-
thetized dogs using a randomized block design.
Following these studies, a bronchial vehicle
challenge (study b) was added and performed
randomly in 8 of 10 dogs. As described in the
table, the experiments consisted of a control
study using the alveolar delivery system to
deliver the vehicle phosphate-buffered saline
(PBS), pH 7.4, predominantly to the alveolar
region of the lung (study a); a control study
using the bronchial delivery system to deliver
the vehicle predominantly to the bronchial
region of the lung (study b); histamine delivery
at a low dose using the bronchial delivery sys-
tem to deliver predominantly to the bronchial
region of the lung (study c); histamine delivery
at a high dose using the alveolar delivery sys-
tem to deliver predominantly to the alveolar
region of the lung, keeping the bronchial dose
the same as in study c (study d); and histamine
delivery at a high dose using the bronchial
delivery system to deliver predominantly to the
bronchial region of the lung, keeping the total
mass the same as in study d (study e). These
five studies also included a vehicle pretreat-
ment challenge with 0.9% saline using the
alveolar delivery system. These pretreatments
were control deliveries for studies f–hin which
nedocromil sodium (Fisons Corp.) dissolved in
0.9% saline was delivered as the pretreatment
agent. The effect of nedocromil pretreatment
on the alveolar histamine-induced changes in
the physiologic parameters measured were
investigated in studies f–i. Following a 20-min
stabilization period, data collection com-
menced. Baseline data were collected for 15
min before aerosol pretreatment with 0.9%
saline or 0.01, 0.1, 1.0 mg/mL (alveolar deliv-
ery) or 0.4 mg/mL (bronchial delivery)
nedocromil in 0.9% saline. Fifteen minutes
later either PBS or 8 mg/mL histamine
diphosphate (ICN Biochemicals, Cleveland,
OH, USA) in PBS was aerosolized and data
were acquired for 90 min. Blood chemistry
values were recorded during the baseline
phase, the pretreatment phase, and at 5, 10,
60, and 90 min during the treatment phase.
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Table 1. Experimental study design.
Pretreatment Treatment Dose (µg)
Study Agent Site Agent Site Agent B A T
a sal (5)a A PBS (10)a Ah i s 0 00
b sal (5) A PBS (33) B his 0 0 0
c sal (5) A his (4) B his 16 6 22
d sal (5) A his (10) A his 16 168 184
e sal (5) A his (33) B his 132 53 185
f ned (5) A A ned 0.01 0.1 0.11
his (10) A his 16 168 184
g ned (5) A A ned 0.1 1.0 1.1
his (10) A his 16 168 184
h ned (5) A ned 1.0 10.0 11.0
his (10) A his 16 168 184
i ned (5) B ned 1.0 0.4 1.4
his (10) A his 16 168 184
Abbreviations: A, alveolar dose; B, bronchial dose; his, histamine; ned, nedocromil; sal, 0.9% saline; T, total dose. aNumbers in paren-
theses refer to the number of breaths. Yeates et al.
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Each of these separate experiments (a–i) lasted
approximately 2.5–4 hr. Of the 88 studies
performed, pulmonary data from 1 dog in
study b and 1 dog in study g were excluded
from the analysis because of problems with
the data acquisition program.
Intravenous Histamine Challenge
To determine the contribution to the car-
diopulmonary responses due to histamine in
the blood, 200 µg of histamine in PBS were
administered iv to 8 of 10 dogs in a tenth
study. These experiments were performed in
anesthetized beagles following completion of
all the histamine inhalation challenge studies.
After a 20-min stabilization period, baseline
data were collected for 15 min, followed by iv
histamine injection. The duration of the injec-
tion was 1.5 min (to approximate the hista-
mine aerosol inhalation time). During the
histamine injection, a sham challenge consist-
ing of 10 breaths of 0.9% saline aerosol was
delivered to the alveolar region using the alve-
olar delivery system. Subsequent measure-
ments of CBFt and ventilatory and pulmonary
function parameters were collected for 1 hr in
8 dogs, followed by iv PBS injection with a
sham inhalation challenge and another 15
min of data collected from 7 of 8 dogs. Blood
chemistry data were recorded 5 min before
and 5, 10, and 60 min after the iv histamine
challenge, and 5 and 10 min after the iv PBS
challenge. Each experiment lasted 2–3.5 hr.
Histamine Challenges Following
Vagotomy
The vagal contributions to the effects of hist-
amine observed in studies d and e and in the
iv histamine study were assessed by perform-
ing a bilateral cervical vagotomy in a terminal
study in 8 of 10 dogs. Following anesthesia
and a 20-min stabilization period, 15 min of
baseline data were collected. The vagosympa-
thetic trunks were exposed and data collected
for 15 min (prevagotomy period). The right
and left vagus nerves were cut simultaneously
and data collected for 15 min (postvagotomy
period). Next, histamine (200 µg) was
injected iv followed by a 30-min data collec-
tion period. Following this, 10 breaths of his-
tamine were delivered by the alveolar delivery
system and 30 min of data collected. The last
challenge in sequence consisted of 33 breaths
of histamine delivered by the bronchial deliv-
ery system and 1 hr of data collection. Blood
chemistry data were recorded at 10 min dur-
ing the baseline, prevagotomy, and postvago-
tomy period; 5 and 10 min after iv histamine;
5 and 10 min after the alveolar histamine
challenge; and 5, 10, and 60 min after the
bronchial histamine challenge. Each experi-
ment lasted 4–6 hr.
Ragweed studies. The animal preparation
and protocols have been described previously
in detail (11). The animal preparation and
protocols were similar to those in which hist-
amine was targeted primarily to the bronchial
and alveolar regions of the lungs but with the
anesthetic being a combination of propofol
and etomidate. 
Statistics
All data are presented as the mean ± SE unless
noted otherwise. The Wilcoxon signed rank
test was used to test for differences between
treatments for nonparametric data. If the data
were normally distributed, the paired t-test
was used. One-tailed significance was
assigned at p < 0.05.
Results
Bronchial and Alveolar Deposition
Patterns
Scintigrams as those in Figure 1A and 1B show
the deposition patterns from bronchial and
alveolar depositions. Such patterns were seen
in both the histamine and ragweed studies.
Cardiovascular and Respiratory
Responses to Histamine
The mean temporal changes in respiration
and pulmonary mechanics due to low-dose
bronchial histamine, high-dose alveolar hista-
mine, and high-dose bronchial histamine are
shown in Figure 2A, 2B, and 2C, respec-
tively. The low bronchial dose of histamine
did not cause any significant change in the
mean pulmonary mechanics parameters when
compared to mean control values of all dogs
Figure 2. Temporal pulmonary mechanics data after PBS control aerosols (n = 7 for bronchial control and n = 10 for alveolar control) and histamine aerosols for the (A) low
bronchial histamine challenge (n = 10) , (B) high alveolar histamine challenge (n = 10), (C) and high bronchial histamine challenge (n = 10). Data were averaged over 1-min periods
beginning with 0–1 min through 25–26 min, followed by 5- and then 10-min averages for each dog study. Each datum point represents the mean of the averaged data for all dogs.
Vehicle or histamine inhalation begins at 1 min.
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ABCAllergen/mediator-induced cardiopulmonary responses
(Figure 2A), although there appeared to be a
small increase in MV not related to an
increase in RR. Any changes in these parame-
ters observed during the high alveolar chal-
lenge must therefore be the result speciﬁcally
of alveolar-induced changes. There was no
appreciable effect of the low bronchial dose of
histamine on partial pressure of CO2 in arter-
ial blood (PCO2) at any time point.
The maximal mean histamine-induced
changes in respiration, pulmonary mechan-
ics, heart rate, and BP for the alveolar depo-
sition, bronchial deposition and iv
administration for similar total doses of hist-
amine are shown in Table 2. Bronchial and
alveolar deposition of histamine caused
apneas of 58 ± 11 sec and 56 ± 9 sec, respec-
tively. No apnea was observed during the iv
delivery of histamine. RR doubled and MV
increased 1.7 times 6–7 min following alveo-
lar and bronchial histamine, whereas there
were no signiﬁcant increases in these parame-
ters following iv administration of histamine.
RL increased by more than a factor of 2 fol-
lowing both alveolar and bronchial hista-
mine, although the increase following
bronchial histamine did not reach statistical
signiﬁcance (p < 0.07). These increases in RL
were maximal at 3 min posthistamine
administration for all routes of administra-
tion and returned to control values within
9–10 min. Minimal changes were observed
in RR and MV following iv histamine
administration. Following either bronchial or
alveolar histamine, substantial decreases in
Cdyn occurred between 3 and 10 min, with
the bronchial histamine causing a greater
decrease in Cdyn in 9 of 10 dogs. Again, any
changes in pulmonary mechanics following
iv histamine were minimal. Following alveo-
lar histamine there were secondary increases
in RL and decreases in Cdyn at 45 min as well
as a concurrent increase in RR (Figure 2B).
There was also a secondary increase in RL 40
min after the bronchial histamine challenge
(Figure 2C). These secondary responses were
not observed following iv histamine.
Changes in heart rate due to alveolar hista-
mine were unremarkable. Small decreases in
heart rate were observed immediately
following bronchial histamine. The decreases
in systolic BP were significant for all treat-
ments but were most dramatic following iv
histamine. The high alveolar histamine dose
caused a small increase in PCO2 at 5 min; it
returned to a near-baseline level by 10 min.
The high bronchial histamine dose caused a
greater increase in PCO2 at 5 min than the
high alveolar histamine dose and, unlike with
the high alveolar histamine dose, PCO2 did
not return to near baseline levels until some
time after the 10-min reading. The changes
in partial pressure of O2 in arterial blood
(PO2) reflected the changes in PCO2.
Intravenous administration of histamine did
not appreciably affect PCO2 or PO2 at
any time. In these experiments, any effects of
histamine on CBFt were not evident.
Also, nedocromil pretreatment did not
affect CBFt.
Effects of Nedocromil on 
Histamine-Induced Pulmonary 
and Vascular Responses
Nedocromil administration to the alveolar
and bronchial regions of the lung at all doses
attenuated the RR and MV responses to alve-
olar histamine beginning at 4–5 min. Initially
this appeared to be independent of dose but
was more clearly dose dependent at 20 min.
Nedocromil abolished the second rise in Cdyn
occurring at 40–45 min (data not shown).
At 20 min, RR with histamine alone was 26 ±
8 breaths (br)/min and after alveolar
nedocromil pretreatments of 0.1, 1, and 10
µg was 20 ± 8, 16 ± 4, and 14 ± 3 br/min,
respectively. Similarly, following bronchial
deposition of 1 µg of nedocromil, RR was 14
±2   br/min. At 20 min, MV with histamine
alone was 3.4 ± 0.8 L/min and after each
alveolar pretreatment with nedocromil was
2.8 ± 0.6, 2.3 ± 0.3, and 1.8 ± 0.2 L/min,
respectively. Similarly, following bronchial
pretreatment with 1 µg of nedocromil, MV
was 2.2 ± 0.2 L/min. Surprisingly, the lowest
alveolar nedocromil dose decreased the peak
RL response the most. Peak RL decreased
from 6.4 ± 1.1 cmH2O L/sec to 4.9 ± 0.6,
5.4 ± 0.6, and 6.1 ± 1.0 cmH2O L/sec,
respectively. There was no attenuation of the
histamine-induced increases in RL due to
bronchial deposition of nedocromil. In this
case RL was 7.0 ± 1.7 cmH2O L/sec. Not
only did nedocromil not prevent the
decreases in Cdyn induced by histamine, the
return to control levels was delayed approxi-
mately 20 min at all doses of nedocromil
independent of its site of deposition. Prior
deposition of nedocromil to the alveolar
region at either the lowest or highest concen-
trations did not affect the decrease in systolic
blood pressure caused by the high alveolar
histamine challenge, 39 ± 4 versus 34 ± 4
mmHg, (p = 0.37), and 31 ± 5 versus 34 ± 4
mmHg (p = 0.425), respectively. 
The effects on PCO2 and PO2 due to alve-
olar histamine following pretreatment with
nedocromil are shown in Figure 3A and 3B,
respectively. When the dogs were pretreated
with nedocromil, the increases in PCO2 due to
histamine delivery to the alveoli were amelio-
rated in a dose-dependent manner. Not sur-
prisingly, nedocromil delivered to the alveolar
region was more effective in attenuating the
increase in PCO2 due to alveolar histamine
than the same dose of nedocromil (1 µg
deposited) delivered to the bronchi. The
effects of histamine with nedocromil on PO2
values were physiologically consistent with
the changes in PCO2.
Effects of Vagotomy on the 
Histamine-Induced Respiratory 
and Cardiac Responses
The influence of bilateral transection of the
cervical vagosympathetic trunk on the tempo-
ral respiratory responses initiated by iv hista-
mine, high-dose alveolar histamine aerosol,
and high-dose bronchial histamine aerosol
can be summarized as follows. The ventila-
tory responses to histamine were abolished
after cutting the vagosympathetic trunks, as
demonstrated by the ablation of the increases
in RR. The RL at 3 min increased from 5.0 ±
0.5 cmH2O L/sec (postvagotomy) to 6.5 ±
0.8 cmH2O L/sec after iv histamine, 7.6 ±
1.9 cmH2O L/sec after alveolar histamine
delivery, and 8.9 ± 1.9 cmH2O L/sec after
bronchial histamine delivery. RL values
returned to near–post-transection baseline
values by 6 min after iv histamine and by 9
min after alveolar histamine, whereas after
bronchial histamine RL did not return to
baseline level throughout the duration of the
study. Sectioning of the vagosympathetic
trunks abolished the histamine-induced
decreases in Cdyn.
As the vagotomy, per se, changed the
baseline respiratory parameters, i.e., decreased
RR and increased VT, peak changes from
baseline for RR, RL, and Cdyn were compared
to peak changes when the vagosympathetic
trunks were intact. It can be seen in Figure
4A that sectioning the vagosympathetic
Environmental Health Perspectives • VOLUME 109 | SUPPLEMENT 4 | August 2001 517
Table 2. Respiratory and cardiovascular peak responses.a
High alveolar  High bronchial Intravenous
Control Histamine Control Histamine Control Histamine
RR (br/min) 13 ± 2 31 ± 9* 15 ± 2 36 ± 9 (NS) 15  ± 2 19 ± 5 (NS)
MV (L/min) 2.1 ± 0.1 3.5 ±0.6* 2.1 ± 0.2 3.6 ± 0.6* 2.4 ± 0.2 2.9 ±0.3 (NS)
RL (cmH2O/sec) 2.6 ± 0.3 6.1 ± 1.1** 3.2 ± 0.6 7.2 ± 1.6 (NS) 3.4 ± 0.4 3.9 ± 0.5 (NS)
Cdyn (mL/cmH2O) 41.9 ± 2.4 31.5 ± 4.4* 37.0 ± 4.0 22.2 ±6.1** 31.9 ± 4.1 24.4 ± 4.3 (NS)
HR (beats/min) 114 ± 10 115 ± 10 (NS) 127 ± 22 116 ± 9* 120 ± 12 112 ± 8 (NS)
BP (mmHg) 177 ± 9 144 ± 8*** 180 ± 14 152 ± 14** 180 ± 7 109 ± 10***
PCO2 (mmHg) 41.9 ± 1.3 46.0 ± 2.3* 41.6 ± 1.6 48.8 ± 2.2** 48.8 ± 0.9 48.6 ± 1.8 (NS)
PO2 (mmHg) 93.0 ± 3.4 74.4 ± 7.3* 94.6 ± 2.3 56.0 ± 7.1** 93.6 ± 2.7 87.5 ± 6.6 (NS)
NS, not signiﬁcant.
aHistamine PCO2 and PO2 are from the 5-min posthistamine blood samples. *p ≤ 0.05; **p ≤ 0.005; ***p ≤ 0.00005.Yeates et al.
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trunks totally abrogated any increases in RR
induced by iv, alveolar, and bronchial deliv-
ery of histamine. The effects of vagotomy on
histamine-induced increases in RL tell a dif-
ferent story (Figure 4B). Small changes in RL
induced by iv histamine did not appear to be
attenuated by transection of the vagosympa-
thetic trunks. The average changes in RL
induced by iv histamine when the vagi were
intact compared to when they were sectioned
were not significant (1.2 ± 0.3 vs 1.7 ± 0.6
cmH2O L/sec). The differences in RL after
bronchial and alveolar histamine challenges
following vagosympathetic trunk transection
are best illustrated by contrasting the patterns
of response in Figure 4B. It can be seen that
sectioning the vagosympathetic trunks
followed by the alveolar histamine challenge
decreased RL in 6 of 8 dogs. There was a
noted exception in one dog; however, these
changes were not statistically significant.
When histamine was deposited primarily in
the bronchial regions, the change in RL
increased in 5 of 8 dogs; in 3 dogs it was
markedly augmented. However, there was no
significance in the mean change. The mean
change in RL after the alveolar histamine
challenge was 3.7 ± 1.2 cmH2O L/sec (intact)
versus 3.5 ± 2.2 cmH2O L/sec (postvago-
tomy) and 4.7 ± 1.1 cmH2O L/sec (intact)
versus 6.5 ± 2.0 cmH2O L/sec (postvago-
tomy) for the bronchial histamine challenge.
Bilateral sectioning of the vagosympathetic
trunks attenuated the histamine-induced
increases in Cdyn whether histamine was
administered iv or predominantly to the
bronchi or alveoli (p < 0.05) (Figure 4C).
The heart rate increased only slightly fol-
lowing transection of the vagosympathetic
trunks (103 ± 9 vs 107 ± 10 beats/min, p =
0.13). There were nonsignificant changes in
heart rate after iv histamine (107 ± 10 vs 97 ±
11 beats/min, p = 0.13), alveolar histamine
(107 ± 10 vs 121 ± 12 beats/min, p < 0.11),
and bronchial histamine (107 ± 10 vs 111 ±
12 beats/min, p = 0.44) when the vagosympa-
thetic trunks were cut. Mean systolic BP was
not signiﬁcantly increased following transec-
tion of the vagosympathetic trunks (170 ± 5
vs 175 ± 8 cmH2O, p = 0.16). The immedi-
ate response of systolic BP to iv, alveolar, and
bronchial histamine was in the same rank
order and of similar magnitude whether the
vagosympathetic trunks were intact, suggest-
ing only a minor role for vagosympathetic
transmission in the histamine-induced
decreases in BP.
During the studies in which the vagosym-
pathetic trunks were cut, iv histamine caused
an increase in PCO2 from 43.5 ± 1.8 to 46.4
2.8 mmHg after 5 min and to 50.1 ± 3.2
mmHg after 10 min. The corresponding
changes in PO2 were from 89.0 ± 4.1 to 78 ±
6.0 and 66.5 ± 8.2, respectively. Alveolar hist-
amine caused the PCO2 to increase to 48.3 ±
1.8 mmHg at 5 min, which dropped to 47.3
± 2.1 mmHg at 10 min. The corresponding
changes in PO2 were 71.8 ± 5.9 mmHg and
76 ± 6.2 mmHg, respectively. Bronchial hist-
amine caused the PCO2 to increase to 49.0 ±
2.9 mmHg at 5 min and to 48.4 ± 2.9
mmHg at 10 min and decrease to a near base-
line value of 46.4 ± 2.2 mmHg at 60 min.
The corresponding changes in PO2 were from
72.7 ± 8.3, 75.9 ± 8.0, and 76.8 ± 8.8
mmHg, respectively. The effects of histamine
challenges on PO2 were consistent with the
effects observed for PCO2. Sectioning of the
vagosympathetic trunks and histamine chal-
lenges post-transection did not have an effect
on CBFt at any time. 
Cardiovascular Responses to Bronchial
and Alveolar Depositions of Ragweed 
in Ragweed-Sensitized Dogs
The cardiac and vascular responses to alveolar
ragweed are shown in Figure 5A. There was a
marked decrease in both heart rate and BP
that were maximal after 1 min following the
end of alveolar ragweed inhalation. The
decreases in BP due to allergen inhalation
were evident in the measurements of both
systolic and diastolic pressures. Even though
the time of delivery of histamine and ragweed
were similar, the marked precipitous fall in
heart rate observed after alveolar allergen
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inhalation was not observed after histamine
inhalation, although both histamine and rag-
weed inhalation resulted in marked decreases
in BP. In these 5 dogs, allergen challenge
induced rapid shallow breathing, with the res-
piratory rate increasing from 11.2 to 134
br/min and the minute ventilation increasing
from 1.5 L/min to 5.2 L/min. It is notable
that the maximal changes in respiration and
in the mechanical properties of the lungs
occurred 10–14 min after the ragweed chal-
lenge (Figure 5B).
Discussion
Partitioning of aerosol deposition to the
bronchial and alveolar lung regions was cru-
cial to the investigation of site specific–
initiated changes in cardiopulmonary func-
tion. The lack of responses observed in the
experiments consisting of a low bronchial
dose of histamine (16 µg) using the bronchial
mode of deposition confirmed that the
responses to high-dose alveolar histamine
using the alveolar mode of deposition were
due to the alveolar dose of histamine (168 µg)
and not to the 16 µg deposited in the
bronchial airways. The changes in lung func-
tion observed with histamine aerosols could
not be attributed to circulating histamine
because the same total dose of iv histamine
was without substantial effect on lung para-
meters, and changes, if any, were transient.
This minimal iv effect on pulmonary
mechanics conﬁrms that the observed respira-
tory responses were not caused by histamine
acting centrally (10). Histamine released from
mast cells is transferred to the blood with a
half-time of 2.5 min (2), increasing about
750 times to 800 ng/mL (3). The roughly
200 ng/mL resulting from the 200-µg injec-
tion appears well within the physiologic
range but higher than the 6.6 ng/mL mea-
sured by Chrusch et al. (16) following a rag-
weed-induced anaphylactic shock. Thus,
these results are a novel set of experimental
data in which the responses to documented
alveolar, bronchial, and systemic histamine
quantities can be compared to elucidate the
physiologic effects of histamine at these doses
and affector sites. 
The doses of histamine deposited in the
lungs in these studies (approximately 185 µg)
produced more than a 200% increase in RL.
In a study by Wanner et al. (17), 110 µg pro-
duced a 10% decrease in forced expiratory
volume in 1 sec (FEV1) in healthy humans.
Although they used somewhat different
inhalation protocols, it was concluded that the
bronchial responsiveness correlated with the
mass of histamine deposited rather than with
the the deposition pattern. Our data, obtained
from extreme deposition patterns resulting in
markedly different concentrations of hista-
mine in terms of location and surface area
distribution, concur with this conclusion. At
variance with this are the results of Rufﬁn et
al. (18), who reported that the dose of hista-
mine sufficient to cause a 20% decrease in
FEV1 (PD20) for central and diffuse deposi-
tion patterns were 6 and 34 µg of histamine
deposited, respectively. The 200 µg we slowly
administered iv gave minimal if any changes
in RL and contrasted with the 500, 5,000, and
50,000 µg boluses of histamine administered
iv to paralyzed pentobarbital-anesthetized
dogs (19). Using those high doses and that
anesthetic regime, nonvagally mediated
increases in bronchoconstriction could be
anticipated (20–22).
Because all changes in RR (including any
increase cause by iv histamine) were ablated
by transection of the vagosympathetic trunk,
it is clear that histamine-induced increases in
RR were initiated in the lungs and mediated
via afferents that traverse the vagosympathetic
trunk. When the histamine deposition was
predominantly bronchial, the increase in RR
was likely due to the stimulation of bronchial
C ﬁbers (8) or rapidly adapting sensory nerves
(6,8). When the deposition was predomi-
nantly peripheral, the increase was likely due
to alveolar C fibers, as these are the major
determinants of irritant-induced increases in
respiratory rate (6). Although pulmonary C
ﬁbers respond to inhaled histamine (6), they
may not be as sensitive to inhaled histamine
as bronchial C ﬁbers (7). It appears from our
studies described herein that the integrated
response in the alveoli is similar to the inte-
grated response from the bronchial C fibers
and rapidly adapting sensory nerves. These
increases in RR likely were initiated at ﬁrst by
activation of H1 and H2 receptors on sensory
nerves, as antagonists to each of these recep-
tors abolished the increase in RR due to
inhaled micron-sized histamine aerosols, as
shown in baboons (23). The RR responses
peaked at a later time than the peak response
in RL and lasted longer than the increases in
RL. This is consistent with the notion that the
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Figure 4. Effect of vagosympathetic trunk transection on the change in (A) respiratory rate, (B) lung resistance, and
(C) dynamic compliance from baseline after iv high alveolar and high bronchial histamine challenges (n = 8). The
mean baseline value for each dog (mean of the first 6 min of averaged data) was subtracted from the value post-
challenge showing the greatest change (1-min averaged value occurring in less than 6 min).
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sensory nerves responsible for the regulation
of respiratory rate are independent of those
that regulate bronchomotor tone, although
both C fibers and rapidly adapting sensory
nerves may play a role in both responses (9). 
The observations that the immediate
marked decreases in BP were not due to com-
mensurate decreases in heart rate, that these
decreases were progressively larger when simi-
lar masses of histamine were administered
predominantly to the bronchi, alveoli, and iv,
and that these decreases were only slightly
attenuated by transection of the vagosympa-
thetic trunks indicate that the major portion
of these histamine-induced decreases in BP
were likely due to pulmonary vasoconstric-
tion and systemic vasodilation, as previously
reported in dogs (24); both effects were
markedly ameliorated by combined H1 and
H2 blockade. 
Although in a similar canine model of
ragweed-induced anaphylaxis an iv dose of
100–80,000 µg was required to produce the
anaphylactic shock (16), only 0.4–1.8 µg of
ragweed allergen was required for deposition
by aerosol in the lungs (11). This 250- to
40,000-fold difference may be due to the
direct delivery of the allergen to the primary
target organ, the decrease in allergen sensitiv-
ity in pentobarbital-anesthetized compared to
propofol/etomidate-anesthetized dogs, or
some other factor. We have preliminary data
that suggest the anesthetic regime may play a
major role. 
The precipitous decrease in heart rate may
be attributable to a neural reflex initiated in
the lungs and or to the direct activation of
cardiac mast cells (25) by antigen permeating
into the blood; we consider the former more
likely. The decreases in BP induced by rag-
weed challenge in the alveoli appeared to
occur proportionately in both systolic and
diastolic pressure. Although a decrease in left
ventricular function as observed by Chrusch
and colleagues (16) cannot be ruled out, it is
likely that this decrease was caused by a
decrease in heart rate and peripheral and sys-
temic vasodilation together with an increase
in pulmonary vascular resistance (26,27).
This decrease in heart rate may be mediated
by H3 receptors (16). The longer temporal
progression of the changes in respiration and
pulmonary mechanics indicate the involve-
ment of mediators and mechanisms other
than those that caused the marked cardiovas-
cular responses. 
The site(s) of bronchoconstriction cannot
be ascertained from these studies and likely
differs between the bronchial and alveolar
deposition patterns. There is some evidence
that the effect of histamine on smooth muscle
tone in the lungs is primarily peripheral
rather than central (28). The results of studies
by Nadel et al. (29) indicate that the principal
sites of constriction were the alveolar ducts
and small bronchioles. Histamine-induced
contraction of smooth muscle is mediated by
H1 receptors (30), which have been shown to
be present in the peripheral lung (31). 
Initially, whether administered by aerosol
to the alveolar or bronchial regions of the
lungs, histamine-induced bronchoconstric-
tion appeared to follow a time course for peak
response similar to those demonstrated by
others (32), with a somewhat more rapid
recovery. Although similar doses of predomi-
nantly bronchial and alveolar histamine
resulted in similar magnitudes of the peak
responses of RL and RR, the high bronchial
histamine dose caused a greater and pro-
longed change in Cdyn, PCO2, and RL.
Between 10 and 30 min, MV was greater for
alveolar than for bronchial histamine, which
may have contributed to the faster improve-
ment in PCO2 levels after alveolar histamine.
The prolonged increase in RL was presumably
due to the high concentration/surface area
activating H1 receptors on bronchial smooth
muscle (30). The increase in RL due to alveo-
lar deposition of histamine was predomi-
nantly caused via activation of pulmonary C
ﬁbers, which through a reﬂex transmitted via
the vagosympathetic trunks mediated the
constriction of smooth muscle in the airways
and alveolar ducts, whereas the increase in RL
following bronchial deposition of histamine
Figure 5. Times and magnitudes of the peak responses of (A) the cardiovascular system and (B) the respiratory system in an average of 5 dogs following the end of inhalation of micro-
gram quantities of ragweed extract for 1–1.4 min using techniques that speciﬁcally targeted deposition in either the bronchial or alveolar regions of the lungs, respectively (11). bpm,
beats per minute; COMP, dynamic compliance; MBP, mean blood pressure; MTPP, mean transpulmonary pressure. 8069, 8124, 8219, 8222, and 8223 indicate the dogs’ numbers. 
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likely was caused by the combined effects of
histamine acting directly on smooth muscle
(30) and local reflex pathways (20). The
decreases in Cdyn appeared greater for
bronchial than for alveolar histamine.
Following bilateral section of the vagosympa-
thetic trunks, the decreases in Cdyn with
bronchial and alveolar histamine were attenu-
ated in all but one dog. A lack of correlation
between in vivo and in vitro responses to hist-
amine on smooth muscle (33) could be
explained by our observation that the
responses mediated by histamine affector
actions are at different sites within the lungs.
To our knowledge no one has followed
the ventilatory and bronchoconstrictive
responses to histamine on a breath-by-breath
basis for as long a length of time as in our
studies (up to 90 min). We were able, there-
fore, to detect physiologic responses with
respect to bronchial versus alveolar deposition
of histamine throughout this extended time
course. There was a prolonged secondary rise
in RL, indicating that histamine caused the
release of a secondary bronchoconstriction-
inducing mediator, an effect that was more
prominent following bronchial histamine
than alveolar histamine delivery. This sec-
ondary rise after bronchial histamine was
abolished after bilateral transection of the
vagosympathetic trunks. The secondary rise
in RR and MV with alveolar histamine but
not with bronchial histamine suggests that a
histamine initiated release of a secondary
mediator, which stimulated pulmonary C
ﬁbers. This latter increase in RR was ablated
by nedocromil, suggesting that nedocromil
either inhibited the release of this mediator or
desensitized pulmonary C ﬁbers. 
Nedocromil sodium had effects on the
physiologic responses to histamine, some of
which are consistent with an inhibition of
activation of sensory nerves, as demonstrated
by the dose-dependent inhibition of RR. The
inhibition by nedocromil of the delayed
changes in RR, RL, and Cdyn could be due to
its inhibition of mobilizing inflammatory
cells, secondary mediator release, plasma
extravasation, or C-ﬁber desensitization (34).
The histamine-induced increase of PCO2
observed at the lowest dose of nedocromil
was attenuated in a dose-dependent manner
at higher nedocromil doses despite dose-
dependent decreases in RR and MV, suggest-
ing that nedocromil decreased the proposed
ventilation and perfusion mismatch by
inhibiting the release of mediators (or by
central inhibition of a tonic efferent pathway
regulating pulmonary vasomotor tone).
However, the initial decreases in Cdyn were
not attenuated by nedocromil and were even
prolonged. Similarly, the increases in RL
were not as greatly attenuated at higher
nedocromil doses as at the lowest dose.
Nedocromil has been reported to stimulate
Cﬁ bers (35) and to inhibit responses due to
the stimulation of sensory nerves (36).
Possibly nedocromil desensitized sensory
fibers for increases in both respiratory rate
and sensory nerves responsible for inhibiting
reﬂex bronchodilation. 
It is remarkable that despite the difference
in surface area between the bronchial and
alveolar regions (300× ), similar masses of cap-
saicin deposited in each of these regions pro-
duced similar stimulations of ciliary beat
frequency (13) and that similar masses of hist-
amine deposited in each of these regions pro-
duced the remarkably similar physiologic
responses reported herein. Neither of these
physiologic responses can be traced to com-
mon systemic origin. Total lung doses of
approximately 185 µg histamine did not stim-
ulate tracheal ciliary beat frequency, whereas
57 µg delivered to the lungs of baboons
caused a delayed stimulation of tracheal ciliary
beat frequency (37). These data suggest that
this stimulation may only be observed at hista-
mine doses below that at which bronchocon-
striction occurs. Alternatively, these dogs may
have been under deeper anesthesia than the
baboons, resulting in a greater barbiturate-
related attenuation of the hypothesized reﬂex.
That sectioning of the vagosympathetic trunks
did not effect CBFt is consistent with our pre-
vious data showing that neither nicotinic gan-
glionic blockade nor muscarinic antagonism
decreased the basal CBFt (38).
Thus, a primary role of histamine is to
increase respiratory rate through vagally trans-
mitted afferent pathways, whether it is
released in the bronchial mucosa or alveolar
interstitium to counteract the increase in
bronchomotor tone and decreased gas
exchange. The histamine-induced increase in
lung resistance appears to have different ori-
gins depending on the site of action (release):
in the alveoli the increased bronchomotor
tone appeared due to reﬂexes transmitted via
the vagosympathetic trunk and in the bronchi
due to direct constriction of smooth muscle
and local reflexes. Histamine transported to
the blood does not play a major role in bron-
choconstriction but does in cardiovascular
responses, especially in the induction of
hypotension. The latter is caused by systemic
vasodilation, pulmonary vasoconstriction,
and decreased cardiac output. Histamine in
the airways initiates secondary responses in
bronchomotor tone that are maximal after 45
min. Nedocromil attenuates the increases in
respiratory rate and lung resistance. In addi-
tion, it abolishes the secondary increases in
bronchomotor tone. 
These studies demonstrate precipitous
decreases in cardiovascular function as soon
as 1 min after inhalation of minute masses of
ragweed allergen and suggest that these are
induced from deposition of the allergen in
both the bronchial and alveolar regions of the
lungs. Although histamine can mimic many
of the responses associated with anaphylaxis,
consistent with the reports of other investiga-
tors, it does not appear to account for all of
the allergen-induced anaphylactic responses.
REFERENCES AND NOTES
1. Yeates DB. Neurally mediated cardiopulmonary responses to
inhaled irritants and antigens. In: Lung Biology in Health and
Disease Series (Lenfant C, ed). Vol 143: Particle-Lung
Interactions (Gehr P, Heyder J, eds). New York:Marcel Dekker,
2000;603–626.
2. White MV, Kaliner MA. Regulation by histamine. In: The Lung:
Scientific Foundations (Crystal RG, West JB, eds). New York:
Raven Press, 1991;927–939.
3. Lazarus SC, Chesrown SE, Frey MJ, Reed BR, Mjördnal TO, Gold
WM. Experimental canine anaphylaxis: cyclic nucleotide, hista-
mine, and lung function. J Appl Physiol Respir Environ Exerc
Physiol 46(5):919–926 (1979). 
4. Fox BT, Bull B, Guz A. Mast cells in the human alveolar wall; an
electronmicroscopic study. J Clin Pathol 34:1333–1342 (1981).
5. Omori C, Schofield BH, Mitzner W, Freed AN. Hyperpnea with
dry air causes time-dependent alterations in nasal morphology
and bronchovascular permeability. J Appl Physiol 78(3):
1043–1051 (1995).
6. Mohammed SP, Higenbottam TW, Adcock JJ. Effects of
aerosol-applied capsaicin, histamine and prostaglandin E2 on
airway sensory receptors of anaesthetized cats. J Physiol 469:
51–66 (1993).
7. Coleridge HM, Coleridge JCG. Impulse activity in afferent vagal
C-fibres with endings in the intrapulmonary airways of dogs.
Respir Physiol 29:125–142 (1977).
8. Roberts AM, Kaufman MP, Baker DG, Brown JK, Coleridge HM,
Coleridge JCG. Reﬂex tracheal contraction induced by stimula-
tion of bronchial C-ﬁbers in dogs. J Appl Physiol Respir Environ
Exerc Physiol 51(2):485–493 (1981).
9. Coleridge HM, Coleridge JCG. Pulmonary reﬂexes: neural mech-
anisms of pulmonary defense. Annu Rev Physiol 56:69–91
(1994).
10. Mussatto DJ, Garrard CS, Lourenco RV. The effect of inhaled
histamine on human tracheal mucus velocity and bronchial
mucociliary clearance. Am Rev Respir Dis 138:775–779 (1988).
11. Yeates D, Daza AV, Mussatto DJ. Bronchial and alveolar aller-
gen-induced anaphylaxis and the stimulation of bronchial
mucociliary clearance in ragweed-sensitized dogs. Proc Assoc
Am Physicians 109:(4):440–452 (1997).
12. Mauser PJ, Edelman NH, Chapman RW. Central nervous system
control of airway tone in guinea pigs: the role of histamine. J
Appl Physiol 65(5):2024–2029 (1988).
13. Eljamal M, Wong LB, Yeates DB. Capsaicin-activated bronchial-
and alveolar-initiated pathways regulating tracheal ciliary beat
frequency. J Appl Physiol 77(3):1239–1245 (1994).
14. Albert RE, Lippmann M, Briscoe W. The characteristics of
bronchial clearance in humans and the effects of cigarette
smoking. Arch Environ Health 18:738–755 (1969).
15. Chandra T, Yeates DB, Miller IF, Wong LB. Stationary and non-
stationary correlation-frequency analysis of heterodyne mode
laser light scattering: magnitude and periodicity of canine tra-
cheal ciliary beat frequency in vivo. Biophys J 66:878–890 (1994).
16. Chrusch C, Sharma S, Unruh H, Bautista E, Duke K, Becker A,
Kepron W, Mink SN. Histamine H3 receptor blockade improves
cardiac function in canine anaphylaxis. Am J Respir Crit Care
Med 160(4):1142–1149 (1999).
17. Wanner AJ, Brodnan M, Perez J, Henke KG, Kim CS. Variability
of airway responsiveness to histamine aerosol in normal sub-
jects. Role of deposition. Am Rev Respir Dis 131:3–7 (1985).
18. Rufﬁn RE, Dolovich MB, Wolff RK, Newhouse MT. The effects
of preferential deposition of histamine in the human airway.
Am Rev Respir Dis 117:485–492 (1978).
19. Lauzon A-M, Dechman G, Martin JG, Bates JHT. Time course of
histamine-induced bronchonconstriction and its adrenergic and
H2 modulation. Respir Physiol 99:127–138 (1995).
20. Shore SA, Bai TR, Wang CG, Martin JG. Central and local
cholinergic components of histamine-induced bronchoconstric-
tion in dogs. J Appl Physiol 58:443–451 (1985).
21. Jackson DM, Richards IM. The effects of pentobarbitone and
chloralose anaesthesia on the vagal component of bronchocon-
striction produced by histamine aerosol in the anaesthetized
Environmental Health Perspectives • VOLUME 109 | SUPPLEMENT 4 | August 2001 521Yeates et al.
522 VOLUME 109 | SUPPLEMENT 4 | August 2001 • Environmental Health Perspectives
dog. Br J Pharmacol 61:251–256 (1977).
22. Islam MS, Ulmer WT. Role of vagus nerves and inhalative
aerosols of acetylcholine and histamine on dynamic pulmonary
elastance in anesthetized spontaneously breathing and artifi-
cially ventilated dog. Res Exp Med (Berl) 181(3):155–170 (1982).
23. Yeates DB, Hameister WM. Alveolar epithelial permeability in
baboons: histamine and capsaicin. J Physiol 450:363–374 (1992).
24. Tucker A, Weir EK, Reeves JT, Grover RF. Histamine H1- and H2-
receptors in the pulmonary and systemic vasculature of the dog.
Am J Physiol 229(4):1008–1013 (1975).
25. Marone G, de Crescenzo G, Florio G, Granata F, Dente V,
Genovese A. Immunological modulation of human cardiac mast
cells. Neurochem Res 24(9):1195–1202 (1999).
26. Mink SN, Becker A, Unruh H, Kepron W. Effects of anaphylaxis
mediators on partitioned pulmonary vascular resistance during
ragweed shock in dogs. J Appl Physiol 84(3):782–790 (1998).
27. Theodorou A, Weger N, Kunke K, Rhee K, Bice D, Muggenberg
B, Lemen R. Ragweed sensitization alters pulmonary vascular
responses to bronchoprovocation in beagle dogs. J Appl Physiol
83(3):912–917 (1997).
28. Pichurko BM, Ingram RH Jr, Sperling RI, Lafleur JE, Corey EJ,
Austen KF, Drazen JM. Localization of the site of the bron-
choconstrictor effects of leukotriene C4 compared with that of
histamine in asthmatic subjects. Am Rev Respir Dis 140:
334–339 (1989).
29. Nadel JA, Corn M, Zwi S, Flesch J, Graf P. Location and mecha-
nism of airway constriction after inhalation of histamine
aerosol and inorganic sulfate aerosol. In: Inhaled Particles and
Vapours. II: Proceedings of the International Symposium of the
British Occupational Hygiene Society (Davies CN, ed).
Oxford/New York:Pergamon Press, 1967;55–67.
30. Chand NB, Dhawan N, Srimal SC, Rahmani NH, Shukla RK,
Altura BM. Reactivity of trachea, bronchi, and lung strips to his-
tamine and carbachol in rhesus monkeys. J Appl Physiol Respir
Environ Exerc Physiol 49(4):729–734 (1980).
31. Casale TB, Rodbard D, Kaliner M. Characterization of histamine
H-1 receptors on human peripheral lung. Biochem Pharmacol
34(18):3285–3292 (1985).
32. Cartier A, Malo J-L, Bégin P, Sestier M, Martin RR. Time course
of the bronchoconstriction induced by inhaled histamine and
methacholine. J Appl Physiol Respir Environ Exerc Physiol 54(3):
821–826 (1983).
33. Armour CL, Lazar NM, Schellenberg RR, Taylor SM, Chan N,
Hogg JC, Paré PD. A comparison of in vivo and in vitro human
airway reactivity to histamine. Am Rev Respir Dis 129:907–910
(1984).
34 Davies RJ. Clinical Implications of the pharmacological profile
of Tilarin. Allergy 51(suppl 28):8–13 (1996). 
35. Jackson DM, Norris AA, Eady RP. Nedocromil sodium and sen-
sory nerves in the dog lung. Pulm Pharmacol 2:179–184 (1989).
36. Eady RP, Jackson DM. Effect of nedocromil sodium on SO2-
induced airway hyperresponsiveness and citric acid-induced
cough in dogs. Int Arch Allergy Appl Immunol 88:240–243
(1989).
37. Hameister WM, Wong LB, Yeates DB. Tracheal ciliary beat fre-
quency in baboons: effects of peripheral histamine and cap-
saicin. Agents Actions 35:200–207 (1992).
38. Wong LB, Miller IF, Yeates DB. Regulatory pathways for the
stimulation of canine tracheal ciliary beat frequency by
bradykinin. J Physiol 422:421–431 (1990).